Dravet Syndrome, Seizure Disorder
Conditions
Keywords
seizure, tonic-atonic, clonic, epilepsy, myoclonic, encephalopathy
Brief summary
Study 1 and Study 3 are the prospective, merged analyses of 2 identical double-blind, placebo-controlled studies, ZX008-1501 and ZX008-1502, to assess the efficacy, safety, and pharmacokinetics of ZX008 when used as adjunctive therapy in pediatric and young adult subjects with Dravet syndrome. Study 1501 and Study 1502 were conducted in parallel; Study 1501 was conducted at approximately 30 study sites in North America; Study 1502 was conducted at approximately 30 study sites in Europe, Asia and Australia. Upon completion of the Baseline Period after initial Screening and Baseline charting of seizure frequency, subjects who qualified for the studies were randomized (1:1:1) in a double-blind manner to receive either 1 of 2 doses of ZX008 (0.2 mg/kg/day or 0.8 mg/kg/day; maximum dose: 30 mg/day) or placebo. Randomization was stratified by age group (\< 6 years, ≥6 to 18 years) to achieve balance across treatment arms, with the target of 25% of subjects in each age group. All subjects were titrated to their randomized dose over a 14-day Titration Period. Following titration, subjects continued treatment at their randomly assigned dose over a 12-week Maintenance Period. Subjects exiting the study underwent a 2-week taper, unless they enrolled in a follow-on study. Subjects were followed for post-study safety monitoring.
Interventions
ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.
DRUGMatching Placebo
Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.
Sponsors
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
2 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Male or non-pregnant, non-lactating female, age 2 to 18 years, inclusive as of the day of the Screening Visit. * Clinical diagnosis of Dravet syndrome, where convulsive seizures are not completely controlled by current antiepileptic drugs. * Must have a minimum # of convulsive seizures per 4-week period for past 12 weeks prior to screening. * All medications or interventions for epilepsy must be stable for at least 4 weeks prior to screening and expected to remain stable throughout the study. * No cardiovascular or cardiopulmonary abnormality based on ECHO, ECG or physical examination. * Parent/caregiver is willing and able to be compliant with diary completion, visit schedule and study drug accountability. Key
Exclusion criteria
* Pulmonary arterial hypertension. * Current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction or stroke. * Current or past history of glaucoma. * Moderate or severe hepatic impairment. * Receiving concomitant therapy with: anorectic agents; monoamine-oxidase inhibitors; medications that act via serotonin including serotonin reuptake inhibitors; atomoxetine, or other centrally-acting noradrenergic agonist; or cyproheptadine. * Currently receiving or has received stiripentol in the past 21 days prior to Screening. * Currently taking carbamazepine, oxcarbamazepine, eslicarbazepine, phenobarbital, or phenytoin, or has taken any of these within the past 30 days. * Positive result on tetrahydrocannabinol (THC) or cannabidiol (CBD) test at the Screening Visit. * A clinically significant medical condition,that would interfere with study participation, collection of study data, or pose a risk to the subject.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo | From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)] | Monthly (28 day) convulsive seizure frequency (CSF) was based on electronic diary data obtained for each participant. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). The number of convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day CSF. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Achieved Greater Than or Equal to 25% (≥25%) Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)] | Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 25% or greater reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period. |
| Percentage of Participants Who Achieved a ≥50% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)] | Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 50% or greater reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period. |
| Percentage of Participants Who Achieved a ≥75% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)] | Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 75% or greater reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period. |
| Percentage of Participants Who Achieved a 100% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)] | Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 100% reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period. |
| Longest Convulsive Seizure-free Interval in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days) | The longest interval between convulsive seizures was calculated over the entire Titration and Maintenance Period and was derived as the maximum of the number of days between consecutive convulsive seizures. |
| Number of Convulsive Seizure-free Days in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days) | A convulsive seizure free day was defined as a day for which diary data are available and no convulsive seizures were reported. Convulsive seizure free days were taken from the electronic diary data. |
| Change From Baseline in Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo | From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)] | Non-convulsive seizures included focal without clear observable motor signs, absence or atypical absence, myoclonic and atonic. The number of non-convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day non-convulsive seizure frequency. |
| Change From Baseline in Convulsive + Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo | From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)] | Total seizure frequency were defined as the combination of convulsive and non-convulsive seizures. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). Non-convulsive seizures included focal without clear observable motor signs, absence or atypical absence, myoclonic and atonic. The seizure frequency was based on electronic diary data obtained for each participant. The number of all seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day convulsive or non-convulsive seizure frequency. |
| Percentage of Participants With Rescue Medication Usage in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)] | Rescue medication was administered according to each participant's usual or prescribed regimen consisting of 1 or more medications. The usage of rescue medication (number of days and number of medications used per seizure episode) was based on electronic diary data obtained for each participant. The number of days rescue medication was taken (normalized to 28 days) was calculated for each participant. Multiple medications taken on the same day were counted once for that day. |
| Percentage of Participants With Hospitalization and Healthcare Resource Utilization to Treat Seizures in Each ZX008 Treatment Arm Compared to Placebo During Study | During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days) | Participants who utilized medical center care to treat a seizure during the study were reported. |
| Percentage of Participants With Status Epilepticus (SE) in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days) | The participants who either had SE episode recorded as an adverse event (AE) during treatment or a seizure greater than 10 minutes were reported for each treatment group. Additionally, a single participant who may had more than one episode of SE, and an episode of SE recorded as both an AE and as a seizure longer than 10 minutes was counted as a single event. |
| Change From Baseline in the Mean Convulsive Seizures Frequency to the Combined Titration and Maintenance Period (T+M) in Participants Receiving ZX008 0.2 mg/kg/Day Compared to Placebo | From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)] | Monthly (28 day) convulsive seizure frequency (CSF) was based on electronic diary data obtained for each participant. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). The number of convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day CSF. |
| Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | At Visit 6 (Day 15), 8 (Day 43), 10 (Day 71) and 12 (Day 99) | CGI-I scale measures improvement in the participant's clinical status from Baseline. The severity of a participant's condition was rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), as follows: 1-very much improved,2-much improved, 3-minimally improved, 4- no change, 5-minimally worse, 6-much worse and 7-very much worse. The Principal Investigator rated their global impression of the participant's condition during the study. |
| Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | At Visit 6 (Day 15), 8 (Day 43), 10 (Day 71) and 12 (Day 99) | CGI-I scale measures improvement in the participant's clinical status from Baseline. The severity of a participant's condition was rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), as follows: 1-very much improved,2-much improved, 3-minimally improved, 4- no change, 5-minimally worse, 6-much worse and 7-very much worse. The Parent/Caregiver rated their global impression of the participant's condition during the study. |
| Change From Baseline to Day 99 in the Quality of Life in Childhood Epilepsy (QOLCE) Score to Measure Quality of Life in Each ZX008 Treatment Arm Compared to Placebo | From Baseline to Day 99 | QOLCE is a low-burden parent/caregiver completed assessment that evaluates how epilepsy affects day-to day functioning of the participant in various life areas, including physical activities, well being, cognition, social activities, behavior, and general health. QOLCE scores items on 16 subscales with possible 5-point response for each, where scores of 5 was best possible response and 1 was worst possible response. Item scores were then transformed to a 0-100 scale as follows: 1-0, 2-25, 3-50, 4-75, 5-100. A score for each participant for each subscale was calculated by averaging that participant's responses to each item in the subscale. Subscale scores per participant were averaged to obtain an overall QoL score for each participant. Higher the subscale and overall QoL scores, better the response. |
| Change From Baseline to Day 99 in the Overall Quality of Life Score From the Pediatric Quality of Life Inventory™ (PedsQL) Score in Each ZX008 Treatment Arm Compared to Placebo | From Baseline to Day 99 | The Pediatric Quality of Life Inventory (PedsQL) is a pediatric modular measure of health related quality of life (QoL) completed by the parent/caregiver on behalf of the participant. It consisted of 23 items across 4 core scales that measure physical (8 items), emotional, social, and school functioning (5 items each). Each of the responses to the 23 items is initially scored on a 5-point Likert scale from 0 (Never) to 4 (Almost always). Scores are linearly transformed to a scale of 0 to 100, where 0=100, 1=75, 2=50, 3=25 and 4=0, and higher scores correspond to better health-related QoL. The Overall Quality of Life is the average of all the items over the number of items answered on all the Scales. |
| Change From Baseline to Day 99 in the Total Score From PedsQL Family Impact Module Score in Each ZX008 Treatment Arm Compared to Placebo | From Baseline to Day 99 | The PedsQL Family Impact measured the impact of pediatric chronic health conditions on parents and the family by measuring parent self-reported physical, emotional, social, and cognitive functioning, communication, worry, and family daily activities and relationships. There are a total of 36 items in the PedsQL: 6 items for Physical Functioning, 5 items each for Emotional Functioning, Cognitive Functioning and Worry, 4 for Social Functioning, 3 for Communication, 3 questions for Daily Activities, and 5 for Family Relationships. Each of the responses are initially scored on a 5-point Likert scale from 0 (Never) to 4 (Almost always) and then linearly transformed to a scale of 0 to 100, where 0=100, 1=75, 2=50, 3=25 and 4=0, and higher scores mean better health-related QoL. |
| Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | At Baseline and Day 99 | The EuroQOL-5 Dimensions-5 Levels scale produced by European QOL Group (EQ-5D-5L) health questionnaire is a health-related QOL instrument with 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5 dimensions of EQ-5D-5L health questionnaire were assessed on a Likert scale with 5 possible levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The categories slight problems, moderate problems, severe problems and extreme problems are collapsed into one response category problems. The QOL of the parent/caregiver was assessed and percentage of participants was reported for each item. |
| Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | From Baseline to Day 99 | The HADS is a tool that was validated to assess presence of anxiety or depression in an outpatient non-psychiatric population. The HADS a 14-item scale that generates ordinal data for 2 dimensions: 1) Anxiety (7 items), and 2) Depression (7 items). Each item has 4 possible answers rated 0 to 3, of which 0 = No distress and 3 = worst distress. All answers to the items for a dimension with their respective rating are added resulting in a range for each dimension from 0-21, out of which of 0-7 = normal; 8-10=borderline abnormal; 11-21=abnormal. Scores for the entire scale (emotional distress) range from 0 to 42, with higher scores indicating more distress. |
| Maximum Observed Concentration of ZX008 Determined Directly From the Concentration Time Profile [Cmax] at Steady State | At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose | Cmax is the maximum observed concentration determined directly from the concentration-time profile. |
| Area Under the Concentration Time Curve of ZX008 From Time Zero to Time 24 Hours [AUC0-24hours] at Steady State | At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose | AUC0-24 is the area under the concentration time curve from time zero to 24 hours. |
| Time to Maximum Concentration [Tmax] of ZX008 at Steady State | At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose | Tmax is the time to maximum concentration at steady state. |
| Elimination Half-life [t1/2 Beta] of ZX008 at Steady State | At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose | t1/2 beta is the elimination half-life. |
| Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | At Baseline and 14 weeks of Titration (2 weeks) and Maintenance Period (12 weeks) | Duration of single convulsive seizures during the Baseline and the duration over the Titration and Maintenance Period were reported by treatment group using categories as \<2 minutes, 2 to 10 minutes and \> 10 minutes as collected in the seizure diary. |
Countries
Australia, Belgium, Canada, Denmark, France, Germany, Italy, Japan, Spain, United Kingdom, United States
Participant flow
Recruitment details
The study 1501 started to enroll participants in January 2016 and concluded in July 2020. The study 1502 started to enroll participants in July 2016 and concluded in July 2020. The consolidated results of Study 1 and Study 3 are included in this record. The Participant Flow refers to the Randomized Population.
Pre-assignment details
Due to slow enrollment into both trials, the databases for the two trials were combined. The first 72 enrolled participants from ZX008-1501 and first 47 from ZX008-1502 were combined for an analysis and reported as Study 1, whereas the final 55 participants from ZX008- 1501 and the final 88 from ZX008-1502 were combined and reported as Study 3.
Participants by arm
| Arm | Count |
|---|---|
| Study 1: Placebo Participants received matching placebo as an oral solution, twice a day (bid) in equally divided doses with food for up to approximately 16 weeks. Study 1 is the merged analysis of 2 identical (ZX008-1501 and ZX008-1502) studies. | 40 |
| Study 1: ZX008 0.2 mg/kg/Day Participants received ZX008 0.2 milligram per kilogram per day (mg/kg/day) as an oral solution, bid, in equally divided doses with food for up to approximately 16 weeks. Study 1 is the merged analysis of 2 identical (ZX008-1501 and ZX008-1502) studies. | 39 |
| Study 1: ZX008 0.8 mg/kg/Day Participants received ZX008 0.8 mg/kg/day as an oral solution, bid, in equally divided doses with food for up to approximately 16 weeks. Study 1 is the merged analysis of 2 identical (ZX008-1501 and ZX008-1502) studies. | 40 |
| Study 3: Placebo Participants received matching placebo as an oral solution, bid, in equally divided doses with food for up to approximately 16 weeks. Study 3 is the merged analysis of 2 identical (ZX008-1501 and ZX008-1502) studies. | 48 |
| Study 3: ZX008 0.2 mg/kg/Day Participants received ZX008 0.2 mg/kg/day as an oral solution, bid, in equally divided doses with food for up to approximately 16 weeks. Study 3 is the merged analysis of 2 identical (ZX008-1501 and ZX008-1502) studies. | 46 |
| Study 3: ZX008 0.8 mg/kg/Day Participants received ZX008 0.8 mg/kg/day as an oral solution, bid, in equally divided doses with food for up to approximately 16 weeks. Study 3 is the merged analysis of 2 identical (ZX008-1501 and ZX008-1502) studies. | 49 |
| Total | 262 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 0 | 5 | 1 | 0 | 2 |
| Overall Study | Death | 0 | 0 | 0 | 1 | 0 | 0 |
| Overall Study | Lack of Efficacy | 1 | 0 | 0 | 1 | 0 | 0 |
| Overall Study | Other | 0 | 0 | 0 | 2 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 2 | 0 | 1 | 0 | 1 | 1 |
Baseline characteristics
| Characteristic | Study 1: ZX008 0.2 mg/kg/Day | Total | Study 1: Placebo | Study 3: ZX008 0.8 mg/kg/Day | Study 3: ZX008 0.2 mg/kg/Day | Study 3: Placebo | Study 1: ZX008 0.8 mg/kg/Day |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 9.0 years STANDARD_DEVIATION 4.52 | 9.2 years STANDARD_DEVIATION 4.65 | 9.2 years STANDARD_DEVIATION 5.1 | 9.5 years STANDARD_DEVIATION 5.29 | 9.6 years STANDARD_DEVIATION 4.42 | 9.0 years STANDARD_DEVIATION 4.29 | 8.8 years STANDARD_DEVIATION 4.41 |
| Age, Customized 12 - < 18 Years | 11 Participants | 76 Participants | 10 Participants | 16 Participants | 15 Participants | 17 Participants | 7 Participants |
| Age, Customized 18 - < 65 Years | 0 Participants | 9 Participants | 3 Participants | 3 Participants | 1 Participants | 0 Participants | 2 Participants |
| Age, Customized 24 Months - <12 Years | 28 Participants | 177 Participants | 27 Participants | 30 Participants | 30 Participants | 31 Participants | 31 Participants |
| Race/Ethnicity, Customized American Indian or Alaska Native | 1 Participants | 2 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 2 Participants | 27 Participants | 4 Participants | 8 Participants | 5 Participants | 7 Participants | 1 Participants |
| Race/Ethnicity, Customized Black or African American | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Not Reported | 2 Participants | 10 Participants | 2 Participants | 1 Participants | 0 Participants | 1 Participants | 4 Participants |
| Race/Ethnicity, Customized Other | 1 Participants | 13 Participants | 2 Participants | 3 Participants | 2 Participants | 4 Participants | 1 Participants |
| Race/Ethnicity, Customized Unknown | 0 Participants | 3 Participants | 0 Participants | 2 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized White | 33 Participants | 205 Participants | 31 Participants | 34 Participants | 37 Participants | 36 Participants | 34 Participants |
| Sex: Female, Male Female | 17 Participants | 125 Participants | 19 Participants | 27 Participants | 22 Participants | 21 Participants | 19 Participants |
| Sex: Female, Male Male | 22 Participants | 137 Participants | 21 Participants | 22 Participants | 24 Participants | 27 Participants | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 40 | 0 / 39 | 0 / 40 | 1 / 48 | 0 / 46 | 0 / 48 |
| other Total, other adverse events | 22 / 40 | 35 / 39 | 36 / 40 | 37 / 48 | 41 / 46 | 41 / 48 |
| serious Total, serious adverse events | 4 / 40 | 4 / 39 | 5 / 40 | 2 / 48 | 3 / 46 | 3 / 48 |
Outcome results
Primary
Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo
Monthly (28 day) convulsive seizure frequency (CSF) was based on electronic diary data obtained for each participant. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). The number of convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day CSF.
Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Population: The modified intent-to-treat (mITT) population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Study 1: Placebo | Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo | -6.71 seizure frequency per 28 days | Standard Deviation 24.263 |
| Study 1: ZX008 0.8 mg/kg/Day | Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo | -13.11 seizure frequency per 28 days | Standard Deviation 25.5 |
| Study 3: Placebo | Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo | 1.54 seizure frequency per 28 days | Standard Deviation 21.966 |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo | -3.54 seizure frequency per 28 days | Standard Deviation 124.132 |
95% CI: [47.72, 72.8]
95% CI: [51.85, 74.19]
Secondary
Area Under the Concentration Time Curve of ZX008 From Time Zero to Time 24 Hours [AUC0-24hours] at Steady State
AUC0-24 is the area under the concentration time curve from time zero to 24 hours.
Time frame: At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose
Population: PK population for each study represents participants randomized to ZX008 and provided concentrations for use in the population PK analysis. PK samples at Visit 8 (Day 43) taken pre-dose to 6 hours post-dose were used to develop a population PK model. The model was utilized to generate plasma concentration-time curve over 24 hours at steady-state in study participants. AUC0-24 was calculated by numerical integration of the individual predicted concentration-time curve.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Study 1: Placebo | Area Under the Concentration Time Curve of ZX008 From Time Zero to Time 24 Hours [AUC0-24hours] at Steady State | 356 nanogram*hour per milliliter (ng*h/mL) | Geometric Coefficient of Variation 37 |
| Study 1: ZX008 0.8 mg/kg/Day | Area Under the Concentration Time Curve of ZX008 From Time Zero to Time 24 Hours [AUC0-24hours] at Steady State | 1390 nanogram*hour per milliliter (ng*h/mL) | Geometric Coefficient of Variation 41.3 |
| Study 3: Placebo | Area Under the Concentration Time Curve of ZX008 From Time Zero to Time 24 Hours [AUC0-24hours] at Steady State | 348 nanogram*hour per milliliter (ng*h/mL) | Geometric Coefficient of Variation 37.1 |
| Study 3: ZX008 0.8 mg/kg/Day | Area Under the Concentration Time Curve of ZX008 From Time Zero to Time 24 Hours [AUC0-24hours] at Steady State | 1290 nanogram*hour per milliliter (ng*h/mL) | Geometric Coefficient of Variation 42.6 |
Secondary
Change From Baseline in Convulsive + Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo
Total seizure frequency were defined as the combination of convulsive and non-convulsive seizures. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). Non-convulsive seizures included focal without clear observable motor signs, absence or atypical absence, myoclonic and atonic. The seizure frequency was based on electronic diary data obtained for each participant. The number of all seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day convulsive or non-convulsive seizure frequency.
Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Study 1: Placebo | Change From Baseline in Convulsive + Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo | -4.45 seizure frequency per 28 days |
| Study 1: ZX008 0.8 mg/kg/Day | Change From Baseline in Convulsive + Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo | -7.40 seizure frequency per 28 days |
| Study 3: Placebo | Change From Baseline in Convulsive + Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo | -22.95 seizure frequency per 28 days |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline in Convulsive + Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo | -1.09 seizure frequency per 28 days |
| Study 3: ZX008 0.2 mg/kg/Day | Change From Baseline in Convulsive + Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo | -6.54 seizure frequency per 28 days |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline in Convulsive + Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo | -11.39 seizure frequency per 28 days |
Secondary
Change From Baseline in Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo
Non-convulsive seizures included focal without clear observable motor signs, absence or atypical absence, myoclonic and atonic. The number of non-convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day non-convulsive seizure frequency.
Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Study 1: Placebo | Change From Baseline in Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo | -9.38 seizure frequency per 28 days |
| Study 1: ZX008 0.8 mg/kg/Day | Change From Baseline in Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo | -4.85 seizure frequency per 28 days |
| Study 3: Placebo | Change From Baseline in Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo | -20.06 seizure frequency per 28 days |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline in Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo | -0.68 seizure frequency per 28 days |
| Study 3: ZX008 0.2 mg/kg/Day | Change From Baseline in Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo | -0.67 seizure frequency per 28 days |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline in Non-convulsive Seizure Frequency to the Combined Titration and Maintenance Period in Each ZX008 Treatment Arm Compared to Placebo | -4.35 seizure frequency per 28 days |
Secondary
Change From Baseline in the Mean Convulsive Seizures Frequency to the Combined Titration and Maintenance Period (T+M) in Participants Receiving ZX008 0.2 mg/kg/Day Compared to Placebo
Monthly (28 day) convulsive seizure frequency (CSF) was based on electronic diary data obtained for each participant. Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). The number of convulsive seizures reported during the entire time interval was divided by the number of nonmissing diary days and the result was then multiplied by 28 to get a 28-day CSF.
Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Study 1: Placebo | Change From Baseline in the Mean Convulsive Seizures Frequency to the Combined Titration and Maintenance Period (T+M) in Participants Receiving ZX008 0.2 mg/kg/Day Compared to Placebo | -6.71 seizure frequency per 28 days | Standard Deviation 24.263 |
| Study 1: ZX008 0.8 mg/kg/Day | Change From Baseline in the Mean Convulsive Seizures Frequency to the Combined Titration and Maintenance Period (T+M) in Participants Receiving ZX008 0.2 mg/kg/Day Compared to Placebo | -18.81 seizure frequency per 28 days | Standard Deviation 90.64 |
| Study 3: Placebo | Change From Baseline in the Mean Convulsive Seizures Frequency to the Combined Titration and Maintenance Period (T+M) in Participants Receiving ZX008 0.2 mg/kg/Day Compared to Placebo | 1.54 seizure frequency per 28 days | Standard Deviation 21.966 |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline in the Mean Convulsive Seizures Frequency to the Combined Titration and Maintenance Period (T+M) in Participants Receiving ZX008 0.2 mg/kg/Day Compared to Placebo | -5.89 seizure frequency per 28 days | Standard Deviation 84.735 |
95% CI: [6.19, 51.33]
95% CI: [31.31, 63.43]
Secondary
Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo
The HADS is a tool that was validated to assess presence of anxiety or depression in an outpatient non-psychiatric population. The HADS a 14-item scale that generates ordinal data for 2 dimensions: 1) Anxiety (7 items), and 2) Depression (7 items). Each item has 4 possible answers rated 0 to 3, of which 0 = No distress and 3 = worst distress. All answers to the items for a dimension with their respective rating are added resulting in a range for each dimension from 0-21, out of which of 0-7 = normal; 8-10=borderline abnormal; 11-21=abnormal. Scores for the entire scale (emotional distress) range from 0 to 42, with higher scores indicating more distress.
Time frame: From Baseline to Day 99
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Study 1: Placebo | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Depression | 0.8 score on a scale | Standard Deviation 4.5 |
| Study 1: Placebo | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Anxiety | -0.4 score on a scale | Standard Deviation 2.68 |
| Study 1: Placebo | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Total emotional distress | 0.4 score on a scale | Standard Deviation 6.45 |
| Study 1: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Depression | 0.2 score on a scale | Standard Deviation 4.52 |
| Study 1: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Anxiety | -0.8 score on a scale | Standard Deviation 2.84 |
| Study 1: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Total emotional distress | -0.6 score on a scale | Standard Deviation 6.6 |
| Study 3: Placebo | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Depression | 0.1 score on a scale | Standard Deviation 4.35 |
| Study 3: Placebo | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Anxiety | -0.8 score on a scale | Standard Deviation 3.33 |
| Study 3: Placebo | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Total emotional distress | -0.7 score on a scale | Standard Deviation 6.82 |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Depression | -0.7 score on a scale | Standard Deviation 3.8 |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Anxiety | -0.6 score on a scale | Standard Deviation 3.62 |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Total emotional distress | -1.2 score on a scale | Standard Deviation 6.42 |
| Study 3: ZX008 0.2 mg/kg/Day | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Depression | 2.0 score on a scale | Standard Deviation 4.77 |
| Study 3: ZX008 0.2 mg/kg/Day | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Anxiety | 0.2 score on a scale | Standard Deviation 3.89 |
| Study 3: ZX008 0.2 mg/kg/Day | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Total emotional distress | 2.2 score on a scale | Standard Deviation 7.52 |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Anxiety | -0.7 score on a scale | Standard Deviation 4 |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Total emotional distress | -1.5 score on a scale | Standard Deviation 6.61 |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in Affective Symptoms of the Parent/Caregiver Using the Hospital Anxiety and Depression Scale (HADS) in Each ZX008 Treatment Arm Compared to Placebo | Depression | -0.8 score on a scale | Standard Deviation 4.03 |
Secondary
Change From Baseline to Day 99 in the Overall Quality of Life Score From the Pediatric Quality of Life Inventory™ (PedsQL) Score in Each ZX008 Treatment Arm Compared to Placebo
The Pediatric Quality of Life Inventory (PedsQL) is a pediatric modular measure of health related quality of life (QoL) completed by the parent/caregiver on behalf of the participant. It consisted of 23 items across 4 core scales that measure physical (8 items), emotional, social, and school functioning (5 items each). Each of the responses to the 23 items is initially scored on a 5-point Likert scale from 0 (Never) to 4 (Almost always). Scores are linearly transformed to a scale of 0 to 100, where 0=100, 1=75, 2=50, 3=25 and 4=0, and higher scores correspond to better health-related QoL. The Overall Quality of Life is the average of all the items over the number of items answered on all the Scales.
Time frame: From Baseline to Day 99
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Study 1: Placebo | Change From Baseline to Day 99 in the Overall Quality of Life Score From the Pediatric Quality of Life Inventory™ (PedsQL) Score in Each ZX008 Treatment Arm Compared to Placebo | -1.6 score on a scale | Standard Deviation 10.43 |
| Study 1: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in the Overall Quality of Life Score From the Pediatric Quality of Life Inventory™ (PedsQL) Score in Each ZX008 Treatment Arm Compared to Placebo | 6.8 score on a scale | Standard Deviation 11.25 |
| Study 3: Placebo | Change From Baseline to Day 99 in the Overall Quality of Life Score From the Pediatric Quality of Life Inventory™ (PedsQL) Score in Each ZX008 Treatment Arm Compared to Placebo | 5.9 score on a scale | Standard Deviation 15.11 |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in the Overall Quality of Life Score From the Pediatric Quality of Life Inventory™ (PedsQL) Score in Each ZX008 Treatment Arm Compared to Placebo | 1.9 score on a scale | Standard Deviation 13.26 |
| Study 3: ZX008 0.2 mg/kg/Day | Change From Baseline to Day 99 in the Overall Quality of Life Score From the Pediatric Quality of Life Inventory™ (PedsQL) Score in Each ZX008 Treatment Arm Compared to Placebo | 4.2 score on a scale | Standard Deviation 17.65 |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in the Overall Quality of Life Score From the Pediatric Quality of Life Inventory™ (PedsQL) Score in Each ZX008 Treatment Arm Compared to Placebo | 2.1 score on a scale | Standard Deviation 14.73 |
Secondary
Change From Baseline to Day 99 in the Quality of Life in Childhood Epilepsy (QOLCE) Score to Measure Quality of Life in Each ZX008 Treatment Arm Compared to Placebo
QOLCE is a low-burden parent/caregiver completed assessment that evaluates how epilepsy affects day-to day functioning of the participant in various life areas, including physical activities, well being, cognition, social activities, behavior, and general health. QOLCE scores items on 16 subscales with possible 5-point response for each, where scores of 5 was best possible response and 1 was worst possible response. Item scores were then transformed to a 0-100 scale as follows: 1-0, 2-25, 3-50, 4-75, 5-100. A score for each participant for each subscale was calculated by averaging that participant's responses to each item in the subscale. Subscale scores per participant were averaged to obtain an overall QoL score for each participant. Higher the subscale and overall QoL scores, better the response.
Time frame: From Baseline to Day 99
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Study 1: Placebo | Change From Baseline to Day 99 in the Quality of Life in Childhood Epilepsy (QOLCE) Score to Measure Quality of Life in Each ZX008 Treatment Arm Compared to Placebo | 1.5 score on a scale | Standard Deviation 8.73 |
| Study 1: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in the Quality of Life in Childhood Epilepsy (QOLCE) Score to Measure Quality of Life in Each ZX008 Treatment Arm Compared to Placebo | 0.8 score on a scale | Standard Deviation 11.77 |
| Study 3: Placebo | Change From Baseline to Day 99 in the Quality of Life in Childhood Epilepsy (QOLCE) Score to Measure Quality of Life in Each ZX008 Treatment Arm Compared to Placebo | 5.8 score on a scale | Standard Deviation 11.7 |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in the Quality of Life in Childhood Epilepsy (QOLCE) Score to Measure Quality of Life in Each ZX008 Treatment Arm Compared to Placebo | 1.2 score on a scale | Standard Deviation 9.01 |
| Study 3: ZX008 0.2 mg/kg/Day | Change From Baseline to Day 99 in the Quality of Life in Childhood Epilepsy (QOLCE) Score to Measure Quality of Life in Each ZX008 Treatment Arm Compared to Placebo | 6.1 score on a scale | Standard Deviation 12.47 |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in the Quality of Life in Childhood Epilepsy (QOLCE) Score to Measure Quality of Life in Each ZX008 Treatment Arm Compared to Placebo | 5.5 score on a scale | Standard Deviation 13.22 |
Secondary
Change From Baseline to Day 99 in the Total Score From PedsQL Family Impact Module Score in Each ZX008 Treatment Arm Compared to Placebo
The PedsQL Family Impact measured the impact of pediatric chronic health conditions on parents and the family by measuring parent self-reported physical, emotional, social, and cognitive functioning, communication, worry, and family daily activities and relationships. There are a total of 36 items in the PedsQL: 6 items for Physical Functioning, 5 items each for Emotional Functioning, Cognitive Functioning and Worry, 4 for Social Functioning, 3 for Communication, 3 questions for Daily Activities, and 5 for Family Relationships. Each of the responses are initially scored on a 5-point Likert scale from 0 (Never) to 4 (Almost always) and then linearly transformed to a scale of 0 to 100, where 0=100, 1=75, 2=50, 3=25 and 4=0, and higher scores mean better health-related QoL.
Time frame: From Baseline to Day 99
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available. Here, number of participants analyzed included those participants who were evaluable for the assessment.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Study 1: Placebo | Change From Baseline to Day 99 in the Total Score From PedsQL Family Impact Module Score in Each ZX008 Treatment Arm Compared to Placebo | -4.4 score on a scale | Standard Deviation 13 |
| Study 1: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in the Total Score From PedsQL Family Impact Module Score in Each ZX008 Treatment Arm Compared to Placebo | 3.9 score on a scale | Standard Deviation 9.44 |
| Study 3: Placebo | Change From Baseline to Day 99 in the Total Score From PedsQL Family Impact Module Score in Each ZX008 Treatment Arm Compared to Placebo | 5.4 score on a scale | Standard Deviation 15.6 |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in the Total Score From PedsQL Family Impact Module Score in Each ZX008 Treatment Arm Compared to Placebo | 1.3 score on a scale | Standard Deviation 14.88 |
| Study 3: ZX008 0.2 mg/kg/Day | Change From Baseline to Day 99 in the Total Score From PedsQL Family Impact Module Score in Each ZX008 Treatment Arm Compared to Placebo | 0.7 score on a scale | Standard Deviation 15.78 |
| Study 3: ZX008 0.8 mg/kg/Day | Change From Baseline to Day 99 in the Total Score From PedsQL Family Impact Module Score in Each ZX008 Treatment Arm Compared to Placebo | 6.3 score on a scale | Standard Deviation 14.64 |
Secondary
Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period
Duration of single convulsive seizures during the Baseline and the duration over the Titration and Maintenance Period were reported by treatment group using categories as \<2 minutes, 2 to 10 minutes and \> 10 minutes as collected in the seizure diary.
Time frame: At Baseline and 14 weeks of Titration (2 weeks) and Maintenance Period (12 weeks)
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Study 1: Placebo | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | <2 min (Baseline) | 69.28 percentage of seizures |
| Study 1: Placebo | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | 2-10 min (Baseline) | 26.86 percentage of seizures |
| Study 1: Placebo | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | >10 min (Baseline) | 3.86 percentage of seizures |
| Study 1: Placebo | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | <2 min (Titration + Maintenance Period) | 71.31 percentage of seizures |
| Study 1: Placebo | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | 2-10 min (Titration + Maintenance Period) | 26.31 percentage of seizures |
| Study 1: Placebo | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | >10 min (Titration + Maintenance Period) | 2.38 percentage of seizures |
| Study 1: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | >10 min (Titration + Maintenance Period) | 2.79 percentage of seizures |
| Study 1: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | >10 min (Baseline) | 0.93 percentage of seizures |
| Study 1: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | 2-10 min (Baseline) | 34.95 percentage of seizures |
| Study 1: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | <2 min (Titration + Maintenance Period) | 71.59 percentage of seizures |
| Study 1: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | 2-10 min (Titration + Maintenance Period) | 25.61 percentage of seizures |
| Study 1: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | <2 min (Baseline) | 64.13 percentage of seizures |
| Study 3: Placebo | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | >10 min (Titration + Maintenance Period) | 4.82 percentage of seizures |
| Study 3: Placebo | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | <2 min (Titration + Maintenance Period) | 72.27 percentage of seizures |
| Study 3: Placebo | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | 2-10 min (Baseline) | 24.22 percentage of seizures |
| Study 3: Placebo | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | >10 min (Baseline) | 4.17 percentage of seizures |
| Study 3: Placebo | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | 2-10 min (Titration + Maintenance Period) | 22.91 percentage of seizures |
| Study 3: Placebo | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | <2 min (Baseline) | 71.61 percentage of seizures |
| Study 3: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | >10 min (Titration + Maintenance Period) | 0.43 percentage of seizures |
| Study 3: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | 2-10 min (Titration + Maintenance Period) | 33.74 percentage of seizures |
| Study 3: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | 2-10 min (Baseline) | 34.83 percentage of seizures |
| Study 3: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | >10 min (Baseline) | 0.96 percentage of seizures |
| Study 3: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | <2 min (Titration + Maintenance Period) | 65.84 percentage of seizures |
| Study 3: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | <2 min (Baseline) | 64.21 percentage of seizures |
| Study 3: ZX008 0.2 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | 2-10 min (Titration + Maintenance Period) | 31.34 percentage of seizures |
| Study 3: ZX008 0.2 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | >10 min (Titration + Maintenance Period) | 5.22 percentage of seizures |
| Study 3: ZX008 0.2 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | 2-10 min (Baseline) | 33.66 percentage of seizures |
| Study 3: ZX008 0.2 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | >10 min (Baseline) | 2.45 percentage of seizures |
| Study 3: ZX008 0.2 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | <2 min (Titration + Maintenance Period) | 63.45 percentage of seizures |
| Study 3: ZX008 0.2 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | <2 min (Baseline) | 63.90 percentage of seizures |
| Study 3: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | >10 min (Baseline) | 3.10 percentage of seizures |
| Study 3: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | <2 min (Baseline) | 74.11 percentage of seizures |
| Study 3: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | 2-10 min (Baseline) | 22.78 percentage of seizures |
| Study 3: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | >10 min (Titration + Maintenance Period) | 1.62 percentage of seizures |
| Study 3: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | <2 min (Titration + Maintenance Period) | 84.67 percentage of seizures |
| Study 3: ZX008 0.8 mg/kg/Day | Distribution of Duration of Convulsive Seizures (in Percentage) in Each ZX008 Treatment Arm Compared to Placebo at Baseline and During the Titration and Maintenance Period | 2-10 min (Titration + Maintenance Period) | 13.71 percentage of seizures |
Secondary
Elimination Half-life [t1/2 Beta] of ZX008 at Steady State
t1/2 beta is the elimination half-life.
Time frame: At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose
Population: PK population for each study represents participants randomized to ZX008 and provided concentrations for use in the population PK analysis.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Study 1: Placebo | Elimination Half-life [t1/2 Beta] of ZX008 at Steady State | 18.4 hours (h) | Geometric Coefficient of Variation 32.3 |
| Study 1: ZX008 0.8 mg/kg/Day | Elimination Half-life [t1/2 Beta] of ZX008 at Steady State | 21.1 hours (h) | Geometric Coefficient of Variation 51.8 |
| Study 3: Placebo | Elimination Half-life [t1/2 Beta] of ZX008 at Steady State | 18.1 hours (h) | Geometric Coefficient of Variation 32.1 |
| Study 3: ZX008 0.8 mg/kg/Day | Elimination Half-life [t1/2 Beta] of ZX008 at Steady State | 18.6 hours (h) | Geometric Coefficient of Variation 42.2 |
Secondary
Longest Convulsive Seizure-free Interval in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period
The longest interval between convulsive seizures was calculated over the entire Titration and Maintenance Period and was derived as the maximum of the number of days between consecutive convulsive seizures.
Time frame: During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days)
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Study 1: Placebo | Longest Convulsive Seizure-free Interval in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 9.50 days |
| Study 1: ZX008 0.8 mg/kg/Day | Longest Convulsive Seizure-free Interval in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 15.00 days |
| Study 3: Placebo | Longest Convulsive Seizure-free Interval in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 25.00 days |
| Study 3: ZX008 0.8 mg/kg/Day | Longest Convulsive Seizure-free Interval in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 10 days |
| Study 3: ZX008 0.2 mg/kg/Day | Longest Convulsive Seizure-free Interval in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 18.5 days |
| Study 3: ZX008 0.8 mg/kg/Day | Longest Convulsive Seizure-free Interval in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 30 days |
p-value: 0.035Wilcoxon rank sum test
p-value: <0.001Wilcoxon rank sum test
p-value: 0.0002Wilcoxon rank sum test
p-value: <0.0001Wilcoxon rank sum test
Secondary
Maximum Observed Concentration of ZX008 Determined Directly From the Concentration Time Profile [Cmax] at Steady State
Cmax is the maximum observed concentration determined directly from the concentration-time profile.
Time frame: At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose
Population: PK population for each study represents participants randomized to ZX008 and provided concentrations for use in the population PK analysis.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Study 1: Placebo | Maximum Observed Concentration of ZX008 Determined Directly From the Concentration Time Profile [Cmax] at Steady State | 17.7 nanograms per milliliter (ng/mL) | Geometric Coefficient of Variation 32.5 |
| Study 1: ZX008 0.8 mg/kg/Day | Maximum Observed Concentration of ZX008 Determined Directly From the Concentration Time Profile [Cmax] at Steady State | 67.9 nanograms per milliliter (ng/mL) | Geometric Coefficient of Variation 37.4 |
| Study 3: Placebo | Maximum Observed Concentration of ZX008 Determined Directly From the Concentration Time Profile [Cmax] at Steady State | 17.4 nanograms per milliliter (ng/mL) | Geometric Coefficient of Variation 32.3 |
| Study 3: ZX008 0.8 mg/kg/Day | Maximum Observed Concentration of ZX008 Determined Directly From the Concentration Time Profile [Cmax] at Steady State | 64.5 nanograms per milliliter (ng/mL) | Geometric Coefficient of Variation 36.6 |
Secondary
Number of Convulsive Seizure-free Days in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period
A convulsive seizure free day was defined as a day for which diary data are available and no convulsive seizures were reported. Convulsive seizure free days were taken from the electronic diary data.
Time frame: During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days)
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Study 1: Placebo | Number of Convulsive Seizure-free Days in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 15.14 seizure free days |
| Study 1: ZX008 0.8 mg/kg/Day | Number of Convulsive Seizure-free Days in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 20.86 seizure free days |
| Study 3: Placebo | Number of Convulsive Seizure-free Days in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 24.43 seizure free days |
| Study 3: ZX008 0.8 mg/kg/Day | Number of Convulsive Seizure-free Days in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 20.20 seizure free days |
| Study 3: ZX008 0.2 mg/kg/Day | Number of Convulsive Seizure-free Days in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 23.36 seizure free days |
| Study 3: ZX008 0.8 mg/kg/Day | Number of Convulsive Seizure-free Days in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 25.33 seizure free days |
Secondary
Percentage of Participants Who Achieved a 100% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period
Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 100% reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period.
Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Study 1: Placebo | Percentage of Participants Who Achieved a 100% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 0 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants Who Achieved a 100% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 7.7 percentage of participants |
| Study 3: Placebo | Percentage of Participants Who Achieved a 100% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 7.5 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants Who Achieved a 100% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants Who Achieved a 100% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants Who Achieved a 100% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 12.5 percentage of participants |
Secondary
Percentage of Participants Who Achieved a ≥50% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period
Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 50% or greater reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period.
Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Study 1: Placebo | Percentage of Participants Who Achieved a ≥50% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 12.5 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants Who Achieved a ≥50% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 38.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants Who Achieved a ≥50% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 67.5 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants Who Achieved a ≥50% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 6.3 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants Who Achieved a ≥50% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 45.7 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants Who Achieved a ≥50% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 72.9 percentage of participants |
p-value: 0.00995% CI: [1.475, 15.45]Regression, Logistic
p-value: <0.00195% CI: [4.484, 49.915]Regression, Logistic
p-value: 0.000195% CI: [3.6, 49.8]Regression, Logistic
p-value: <0.000195% CI: [12.9, 220.5]Regression, Logistic
Secondary
Percentage of Participants Who Achieved a ≥75% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period
Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 75% or greater reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period.
Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Study 1: Placebo | Percentage of Participants Who Achieved a ≥75% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 2.5 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants Who Achieved a ≥75% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 23.1 percentage of participants |
| Study 3: Placebo | Percentage of Participants Who Achieved a ≥75% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 50.0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants Who Achieved a ≥75% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 4.2 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants Who Achieved a ≥75% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 28.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants Who Achieved a ≥75% Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 47.9 percentage of participants |
Secondary
Percentage of Participants Who Achieved Greater Than or Equal to 25% (≥25%) Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period
Convulsive seizures included hemiclonic, focal with clear observable motor signs, generalized tonic clonic, secondarily generalized tonic clonic, tonic, clonic, and drop seizures (tonic/atonic). A responder was a participant who experienced a 25% or greater reduction in convulsive seizure frequency per 28 days during Titration and Maintenance Period.
Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Study 1: Placebo | Percentage of Participants Who Achieved Greater Than or Equal to 25% (≥25%) Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 35.0 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants Who Achieved Greater Than or Equal to 25% (≥25%) Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 66.7 percentage of participants |
| Study 3: Placebo | Percentage of Participants Who Achieved Greater Than or Equal to 25% (≥25%) Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 90.0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants Who Achieved Greater Than or Equal to 25% (≥25%) Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 27.1 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants Who Achieved Greater Than or Equal to 25% (≥25%) Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 71.7 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants Who Achieved Greater Than or Equal to 25% (≥25%) Reduction in Convulsive Seizure Frequency in Each ZX008 Treatment Arm Compared to Placebo From Baseline During the Titration and Maintenance Period | 83.3 percentage of participants |
Secondary
Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo
CGI-I scale measures improvement in the participant's clinical status from Baseline. The severity of a participant's condition was rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), as follows: 1-very much improved,2-much improved, 3-minimally improved, 4- no change, 5-minimally worse, 6-much worse and 7-very much worse. The Principal Investigator rated their global impression of the participant's condition during the study.
Time frame: At Visit 6 (Day 15), 8 (Day 43), 10 (Day 71) and 12 (Day 99)
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 6) | 5.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 8) | 5.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 10) | 10.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 12) | 0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 6) | 40.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 12) | 2.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 12) | 2.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 10) | 35.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 12) | 2.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 10) | 30.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 6) | 5.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 8) | 30.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 6) | 12.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 8) | 30.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 10) | 7.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 12) | 47.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 6) | 0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 10) | 0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 12) | 7.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 10) | 2.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 8) | 12.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 8) | 0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 6) | 0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 10) | 0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 6) | 20.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 12) | 30.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 8) | 2.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 8) | 0 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 8) | 5.1 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 8) | 5.1 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 12) | 17.9 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 8) | 17.9 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 8) | 30.8 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 8) | 20.5 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 12) | 28.2 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 6) | 23.1 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 12) | 12.8 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 10) | 0 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 6) | 12.8 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 12) | 0 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 10) | 2.6 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 6) | 20.5 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 12) | 2.6 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 10) | 7.7 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 10) | 28.2 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 6) | 25.6 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 10) | 25.6 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 6) | 7.7 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 12) | 10.3 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 10) | 17.9 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 10) | 17.9 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 6) | 0 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 8) | 0 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 6) | 0 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 12) | 28.2 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 8) | 5.1 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 10) | 47.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 10) | 0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 6) | 17.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 6) | 25.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 6) | 20.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 6) | 17.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 6) | 5.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 6) | 2.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 6) | 0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 8) | 17.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 8) | 37.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 8) | 10.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 8) | 10.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 8) | 0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 8) | 2.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 8) | 2.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 10) | 20.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 10) | 5.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 10) | 7.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 10) | 0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 10) | 0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 12) | 27.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 12) | 35.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 12) | 15.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 12) | 12.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 12) | 0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 12) | 0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 12) | 2.5 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 12) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 12) | 16.7 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 6) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 12) | 58.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 10) | 10.4 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 8) | 6.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 8) | 16.7 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 6) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 8) | 50.0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 8) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 10) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 12) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 8) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 10) | 12.5 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 6) | 54.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 10) | 60.4 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 8) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 6) | 27.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 12) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 10) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 12) | 6.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 6) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 6) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 10) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 8) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 6) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 12) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 10) | 4.2 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 8) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 12) | 28.3 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 10) | 15.2 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 8) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 10) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 10) | 26.1 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 6) | 2.2 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 6) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 6) | 21.7 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 12) | 28.3 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 12) | 10.9 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 10) | 19.6 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 8) | 10.9 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 12) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 12) | 21.7 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 10) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 8) | 26.1 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 8) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 6) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 8) | 17.4 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 10) | 28.3 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 10) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 8) | 34.8 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 6) | 26.1 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 6) | 17.4 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 6) | 21.7 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 12) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 12) | 8.7 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 8) | 14.6 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 8) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 8) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 6) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 8) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 6) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 10) | 35.4 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 10) | 18.8 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 6) | 12.5 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 10) | 16.7 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 6) | 27.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 10) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 6) | 27.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 10) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 6) | 16.7 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 10) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 12) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 10) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 12) | 31.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 12) | 6.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 12) | 10.4 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 12) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 12) | 16.7 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 8) | 31.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 8) | 29.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 12) | 33.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 8) | 8.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Rating Score, as Assessed by the Principal Investigator in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 6) | 0 percentage of participants |
Secondary
Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo
CGI-I scale measures improvement in the participant's clinical status from Baseline. The severity of a participant's condition was rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), as follows: 1-very much improved,2-much improved, 3-minimally improved, 4- no change, 5-minimally worse, 6-much worse and 7-very much worse. The Parent/Caregiver rated their global impression of the participant's condition during the study.
Time frame: At Visit 6 (Day 15), 8 (Day 43), 10 (Day 71) and 12 (Day 99)
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 12) | 35.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 6) | 45.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 10) | 22.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 6) | 2.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 8) | 15.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 6) | 5.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 6) | 22.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 10) | 12.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 6) | 0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 12) | 7.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 8) | 0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 10) | 2.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 8) | 15.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 10) | 2.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 12) | 7.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 8) | 20.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 12) | 0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 12) | 2.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 12) | 20.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 10) | 2.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 6) | 12.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 8) | 0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 6) | 2.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 8) | 2.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 10) | 12.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 8) | 25.0 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 12) | 17.5 percentage of participants |
| Study 1: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 10) | 32.5 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 8) | 15.4 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 6) | 28.2 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 8) | 25.6 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 8) | 5.1 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 10) | 20.5 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 6) | 12.8 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 12) | 20.5 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 12) | 7.7 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 12) | 0 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 12) | 15.4 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 6) | 17.9 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 6) | 7.7 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 10) | 7.7 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 10) | 25.6 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 10) | 17.9 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 10) | 7.7 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 6) | 2.6 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 12) | 20.5 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 8) | 10.3 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 12) | 15.4 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 10) | 20.5 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 8) | 12.8 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 6) | 0 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 12) | 20.5 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 8) | 25.6 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 8) | 0 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 10) | 0 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 6) | 20.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 8) | 2.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 8) | 37.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 8) | 15.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 8) | 5.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 8) | 5.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 12) | 5.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 8) | 2.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 6) | 22.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 12) | 15.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 10) | 0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 12) | 2.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 10) | 2.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 12) | 27.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 12) | 27.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 12) | 10.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 10) | 0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 6) | 15.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 10) | 10.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 6) | 27.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 8) | 20.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 12) | 5.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 10) | 7.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 6) | 20.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 10) | 30.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 6) | 2.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 6) | 7.5 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 10) | 35.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 6) | 2.5 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 12) | 50.0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 10) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 10) | 6.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 10) | 45.8 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 10) | 6.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 10) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 12) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 6) | 6.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 6) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 6) | 25.0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 6) | 45.8 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 6) | 10.4 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 6) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 6) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 8) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 8) | 8.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 8) | 20.8 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 8) | 47.9 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 8) | 6.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 8) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 8) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 10) | 25.0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 10) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 12) | 6.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 12) | 18.8 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 12) | 10.4 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 12) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 12) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 8) | 30.4 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 12) | 4.3 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 8) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 6) | 2.2 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 6) | 2.2 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 6) | 19.6 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 6) | 26.1 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 10) | 26.1 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 6) | 23.9 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 6) | 13.0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 12) | 13.0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 10) | 4.3 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 12) | 30.4 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 12) | 6.5 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 10) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 10) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 6) | 0 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 12) | 28.3 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 10) | 26.1 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 10) | 28.3 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 10) | 8.7 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 12) | 8.7 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 8) | 6.5 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 8) | 6.5 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 8) | 17.4 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 8) | 28.3 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 12) | 2.2 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 8) | 2.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 12) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 10) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 8) | 14.6 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 8) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 6) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 12) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 8) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 6) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 10) | 22.9 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 8) | 6.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 6) | 31.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 12) | 29.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 12) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 10) | 6.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 10) | 8.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 6) | 31.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 6) | 6.3 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 6) | 16.7 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 2 = Much improved (Visit 8) | 29.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 10) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 4 = No change (Visit 12) | 4.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 5 = Minimally worse (Visit 8) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 7 = Very much worse (Visit 6) | 2.1 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 10) | 41.7 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 6 = Much worse (Visit 10) | 0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 3 = Minimally improved (Visit 12) | 20.8 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 8) | 39.6 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Clinical Global Impression - Improvement Rating Score, as Assessed by the Parent/Caregiver in Each ZX008 Treatment Arm Compared to Placebo | 1 = Very much improved (Visit 12) | 33.3 percentage of participants |
Secondary
Percentage of Participants With Hospitalization and Healthcare Resource Utilization to Treat Seizures in Each ZX008 Treatment Arm Compared to Placebo During Study
Participants who utilized medical center care to treat a seizure during the study were reported.
Time frame: During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days)
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Study 1: Placebo | Percentage of Participants With Hospitalization and Healthcare Resource Utilization to Treat Seizures in Each ZX008 Treatment Arm Compared to Placebo During Study | 22.5 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Hospitalization and Healthcare Resource Utilization to Treat Seizures in Each ZX008 Treatment Arm Compared to Placebo During Study | 17.9 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Hospitalization and Healthcare Resource Utilization to Treat Seizures in Each ZX008 Treatment Arm Compared to Placebo During Study | 15.0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Hospitalization and Healthcare Resource Utilization to Treat Seizures in Each ZX008 Treatment Arm Compared to Placebo During Study | 12.5 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Hospitalization and Healthcare Resource Utilization to Treat Seizures in Each ZX008 Treatment Arm Compared to Placebo During Study | 19.6 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Hospitalization and Healthcare Resource Utilization to Treat Seizures in Each ZX008 Treatment Arm Compared to Placebo During Study | 14.6 percentage of participants |
Secondary
Percentage of Participants With Rescue Medication Usage in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period
Rescue medication was administered according to each participant's usual or prescribed regimen consisting of 1 or more medications. The usage of rescue medication (number of days and number of medications used per seizure episode) was based on electronic diary data obtained for each participant. The number of days rescue medication was taken (normalized to 28 days) was calculated for each participant. Multiple medications taken on the same day were counted once for that day.
Time frame: From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Study 1: Placebo | Percentage of Participants With Rescue Medication Usage in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 77.5 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Rescue Medication Usage in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 59.0 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Rescue Medication Usage in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 45.0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Rescue Medication Usage in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 60.4 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Rescue Medication Usage in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 65.2 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Rescue Medication Usage in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 47.9 percentage of participants |
Secondary
Percentage of Participants With Status Epilepticus (SE) in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period
The participants who either had SE episode recorded as an adverse event (AE) during treatment or a seizure greater than 10 minutes were reported for each treatment group. Additionally, a single participant who may had more than one episode of SE, and an episode of SE recorded as both an AE and as a seizure longer than 10 minutes was counted as a single event.
Time frame: During 14 weeks Titration (2 weeks) and Maintenance Period (12 weeks) (average of 99 days)
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Study 1: Placebo | Percentage of Participants With Status Epilepticus (SE) in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 27.5 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Percentage of Participants With Status Epilepticus (SE) in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 28.2 percentage of participants |
| Study 3: Placebo | Percentage of Participants With Status Epilepticus (SE) in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 35.0 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Status Epilepticus (SE) in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 16.7 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Percentage of Participants With Status Epilepticus (SE) in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 19.6 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Percentage of Participants With Status Epilepticus (SE) in Each ZX008 Treatment Arm Compared to Placebo During the Titration and Maintenance Period | 25.0 percentage of participants |
Secondary
Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99
The EuroQOL-5 Dimensions-5 Levels scale produced by European QOL Group (EQ-5D-5L) health questionnaire is a health-related QOL instrument with 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The 5 dimensions of EQ-5D-5L health questionnaire were assessed on a Likert scale with 5 possible levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The categories slight problems, moderate problems, severe problems and extreme problems are collapsed into one response category problems. The QOL of the parent/caregiver was assessed and percentage of participants was reported for each item.
Time frame: At Baseline and Day 99
Population: The mITT population included all randomized participants who received at least 1 dose of ZX008 or placebo and for whom at least 1 week of diary data were available. Here, Number of participants analyzed included those participants who were evaluable for the assessment and 'n' (Number analyzed) signifies participants who were evaluable at specified time points.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- Problems (Day 99) | 60.00 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- No problems (Day 99) | 40.00 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- Problems (Baseline) | 66.67 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- No problems (Baseline) | 33.33 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- Problems (Day 99) | 51.43 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- Problems (Baseline) | 51.28 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- Problems (Day 99) | 34.29 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- No problems (Day 99) | 65.71 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- No problems (Baseline) | 48.72 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- Problems (Baseline) | 76.92 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- Problems (Baseline) | 25.64 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- No problems (Baseline) | 23.08 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - Problems (Day 99) | 71.43 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- No problems (Baseline) | 74.36 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - No problems (Day 99) | 28.57 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- No problems (Day 99) | 25.71 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - Problems (Baseline) | 74.36 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- Problems (Day 99) | 74.29 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- No problems (Day 99) | 48.57 percentage of participants |
| Study 1: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - No problems (Baseline) | 25.64 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- No problems (Day 99) | 51.35 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- Problems (Day 99) | 54.05 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - No problems (Baseline) | 41.18 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - No problems (Day 99) | 43.24 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- Problems (Baseline) | 58.82 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- Problems (Day 99) | 67.57 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- Problems (Baseline) | 58.82 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- No problems (Baseline) | 61.76 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- No problems (Baseline) | 52.94 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- Problems (Baseline) | 47.06 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- No problems (Day 99) | 45.95 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - Problems (Baseline) | 58.82 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - Problems (Day 99) | 56.76 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- No problems (Baseline) | 41.18 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- No problems (Day 99) | 32.43 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- No problems (Baseline) | 41.18 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- Problems (Day 99) | 48.65 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- Problems (Baseline) | 38.24 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- No problems (Day 99) | 67.57 percentage of participants |
| Study 1: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- Problems (Day 99) | 32.43 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- No problems (Day 99) | 51.35 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - No problems (Baseline) | 38.46 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- Problems (Day 99) | 51.35 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- No problems (Baseline) | 56.41 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- Problems (Day 99) | 32.43 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- Problems (Day 99) | 35.14 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- Problems (Baseline) | 53.85 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - Problems (Baseline) | 61.54 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- No problems (Baseline) | 46.15 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- No problems (Day 99) | 64.86 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - No problems (Day 99) | 48.65 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- No problems (Baseline) | 46.15 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- Problems (Day 99) | 48.65 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - Problems (Day 99) | 51.35 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- No problems (Baseline) | 35.90 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- Problems (Baseline) | 53.85 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- No problems (Day 99) | 67.57 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- Problems (Baseline) | 43.59 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- Problems (Baseline) | 64.10 percentage of participants |
| Study 3: Placebo | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- No problems (Day 99) | 48.65 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- Problems (Day 99) | 47.62 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- No problems (Day 99) | 30.95 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- Problems (Baseline) | 55.00 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - No problems (Day 99) | 30.95 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- Problems (Day 99) | 69.05 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- Problems (Day 99) | 30.95 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- Problems (Baseline) | 60.00 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - No problems (Baseline) | 22.50 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- No problems (Baseline) | 60.00 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- No problems (Day 99) | 76.19 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- No problems (Day 99) | 52.38 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- No problems (Baseline) | 45.00 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- Problems (Baseline) | 40.00 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- No problems (Baseline) | 25.00 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- Problems (Day 99) | 45.24 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- Problems (Baseline) | 75.00 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- No problems (Day 99) | 69.05 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- No problems (Baseline) | 40.00 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - Problems (Baseline) | 77.50 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - Problems (Day 99) | 69.05 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- Problems (Day 99) | 32.56 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- No problems (Day 99) | 51.16 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- Problems (Day 99) | 48.84 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- Problems (Day 99) | 74.42 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - No problems (Baseline) | 36.36 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - Problems (Baseline) | 63.64 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - No problems (Day 99) | 34.88 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- No problems (Day 99) | 67.44 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - Problems (Day 99) | 65.12 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- No problems (Baseline) | 39.39 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- Problems (Baseline) | 60.61 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- No problems (Baseline) | 54.55 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- No problems (Day 99) | 25.58 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- Problems (Baseline) | 48.48 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- No problems (Day 99) | 46.51 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- Problems (Day 99) | 53.49 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- Problems (Baseline) | 45.45 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- No problems (Baseline) | 63.64 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- Problems (Baseline) | 36.36 percentage of participants |
| Study 3: ZX008 0.2 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- No problems (Baseline) | 51.52 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- No problems (Baseline) | 28.57 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- No problems (Baseline) | 74.29 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- Problems (Day 99) | 26.67 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - No problems (Baseline) | 22.86 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - Problems (Baseline) | 77.14 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- No problems (Baseline) | 20.00 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- Problems (Day 99) | 64.44 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- No problems (Day 99) | 73.33 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - Problems (Day 99) | 64.44 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- Problems (Baseline) | 48.57 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Self-care - No problems (Day 99) | 35.56 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- Problems (Baseline) | 80.00 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- No problems (Baseline) | 51.43 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Anxiety/depression- Problems (Baseline) | 25.71 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- Problems (Baseline) | 71.43 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Usual activities- No problems (Day 99) | 35.56 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- Problems (Day 99) | 35.56 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- Problems (Day 99) | 53.33 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Pain/discomfort- No problems (Day 99) | 64.44 percentage of participants |
| Study 3: ZX008 0.8 mg/kg/Day | Quality of Life (QoL) of the Parent/Caregiver Using the EQ- 5D-5L Scale in Each ZX008 Treatment Arm Compared to Placebo at Baseline and Day 99 | Mobility- No problems (Day 99) | 46.67 percentage of participants |
Secondary
Time to Maximum Concentration [Tmax] of ZX008 at Steady State
Tmax is the time to maximum concentration at steady state.
Time frame: At Visit 8 (Day 43): pre-dose, 1, 2, and 4-6 hours postdose
Population: PK population for each study represents participants randomized to ZX008 and provided concentrations for use in the population PK analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Study 1: Placebo | Time to Maximum Concentration [Tmax] of ZX008 at Steady State | 2.90 hours (h) |
| Study 1: ZX008 0.8 mg/kg/Day | Time to Maximum Concentration [Tmax] of ZX008 at Steady State | 3.00 hours (h) |
| Study 3: Placebo | Time to Maximum Concentration [Tmax] of ZX008 at Steady State | 2.90 hours (h) |
| Study 3: ZX008 0.8 mg/kg/Day | Time to Maximum Concentration [Tmax] of ZX008 at Steady State | 2.90 hours (h) |